Tag: therapies

Lennox-Gastaut Syndrome (LGS) Foundation Launches Pre-Competitive Research Accelerator for LGS and Associated Developmental and Epileptic Encephalopathies

SAN DIEGO, June 8, 2026 /PRNewswire/ -- The Lennox-Gastaut Syndrome (LGS) Foundation today announced the launch of the LGS and Associated DEE Research Accelerator,...

Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in...

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /CNW/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical...

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Vi Appoints Spencer Honeyman as President, Global Growth

NEW YORK, June 7, 2026 /PRNewswire/ -- Vi today announced the promotion of Spencer Honeyman to President, Global Growth. ...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /CNW/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Innventure to Participate in Upcoming Investor Conferences

Leverage Shares by Themes Launches 2X Long and 2X Short SpaceX ETFs Following Historic SpaceX IPO

Capital Bank Announces the Appointment of Don Busick to Its Board Leadership Team

Lennox-Gastaut Syndrome (LGS) Foundation Launches Pre-Competitive Research Accelerator for LGS and Associated Developmental and Epileptic Encephalopathies

Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

Vi Appoints Spencer Honeyman as President, Global Growth

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Explore

Press Releases

News & Opinion

Living

Others

Follow us